Introduction:
The article discusses the benefits of developing platform processes for biomanufacturing. It highlights case studies on the platform process development for mRNA manufacturing, scale-up of adenovirus-based COVID-19 vaccine production, and production of allogeneic cell therapies using induced pluripotent stem cells (iPSCs). The platform approach offers advantages such as faster production, scalability, real-time monitoring and control, and cost reduction.
- A platform approach to mRNA manufacturing allows for quick production of therapeutics and vaccines in a disease agnostic manner.
- A web-based application dashboard can be used to monitor and control the mRNA production process in real-time.
- A platform process for adenovirus-based COVID-19 vaccine production enabled smooth process transfer and rapid scalability.
- Developing a platform process for allogeneic cell therapies using iPSCs reduces costs, improves scalability, and ensures better process control.
- Standardizing platforms for manufacturing of advanced therapies and vaccines offer less complexity, better scalability, and tighter process monitoring and control.
Conclusion:
The development of platform processes for biomanufacturing offers numerous benefits, including faster production, scalability, real-time monitoring, and cost reduction. Case studies on mRNA manufacturing, adenovirus-based vaccine production, and allogeneic cell therapies using iPSCs highlight the effectiveness of platform approaches in these areas. Standardizing platforms for advanced therapies and vaccines is considered the way forward for more efficient and effective biomanufacturing processes.
